A Phase 1 Study to Estimate MMAE Metabolites in Human Plasma and Urine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Receiving Brentuximab Vedotin

Trial Profile

A Phase 1 Study to Estimate MMAE Metabolites in Human Plasma and Urine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Receiving Brentuximab Vedotin

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2016

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Rifampicin
  • Indications Anaplastic large cell lymphoma; Hodgkin's disease
  • Focus Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 30 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 23 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 15 Jan 2014 According to ClinicalTrial.gov record, status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top